免疫疗法
医学
肿瘤科
肺癌
PD-L1
内科学
化疗
耐火材料(行星科学)
免疫原性
免疫学
癌症
免疫系统
生物
天体生物学
作者
Yangyang Xu,Ping Zhan,Yong Song
标识
DOI:10.3779/j.issn.1009-3419.2020.105.02
摘要
Small cell lung (SCLC) is a refractory cancer characterized by rapid growth and extensive early metastasis. About 70% of patients are already in the extensive stage at the time of diagnosis. Despite the high response rate to platinum-contained first-line chemotherapy, almost all patients subsequently experienced inevitable recurrence and had poor response to second-line treatment. The high mutation load and immunogenicity of SCLC suggest that immunotherapy may be effective for SCLC patients. Over the past few years, several clinical trials have evaluated the efficacy of checkpoint inhibitors [mainly cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors] in SCLC patients and demonstrated promising survival prospects. This article reviewed the clinical studies of immune checkpoint inhibitors (ICIs) in the first-line, maintenance and second or more line treatment of SCLC. Besides, predictive biomarkers were discussed to select suitable patients for immunotherapy effectively.
科研通智能强力驱动
Strongly Powered by AbleSci AI